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Solid-organ transplantation (heart. lung, liver, kidney. pan-
creas. and intestine) has become a successful and widely 
accepted treatment for a variety of conditions. However. the 
shortage of cadaveric organs is hindering the larger use of this 
therapeutic option. In spite of the progressive evolution of 
public and professional understanding and acceptance of or-
gan donation during the past .30 years. only a little more than 
25% of potential brain-dead organ donors actually donate. H 
As of October .31, 1997, 55.789 transplant candidates were 
registered on the national organ waiting list compiled and 
managed by the United Network for Organ Sharing (UNOS), 
the agency that coordinates organ allocation in the United 
States.' TIlis statistic represents a 580% increase from the 
9.632 patients who were waiting in December 1986, whereas 
the supply of organ donors underwent only a moderate in-
crease between 1988 and 1996 (from ,*.083 to ".-117)'-- (Fig. 
177-1). 
It is estimated that every day seven potential organ recipi-
ents in the United States die before a suitable organ is found" 
Consequently. although the need has increased dramatically. 
we observe with mounting concern the persistent wastage of 
available organs and the death of potential recipients. These 
are both mainly related to an unwillin/mess to donate or a 
lack of awareness regarding donation. as well as delays or 
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Figure 177-1. Organ donor supply in the United States from 1988 
througllI996. 
failure by the medical staff to consider organ donation. J Other 
forces at work also have significantly decreased organ availabil-
ity for the sicker patients, such as a policy implemented b~D 
UNOS in 1991 that substantially changed previous allocatioll 
criteria.9 As a result of this. an even more limited number of 
organs are available for the most severely ill patients, and some 
advocate their outright exclusion from transplant candidacy in 
favor of the elective cases. 10. \I 
Many routes have been explored in an attempt to remedy 
this situation. including the development of artificial organS.ll 
utilization of living donors even for extrarenal organs, 1",,1 
xenotransplantation. 16- 18 and non-heart-beating donors. 19 
However. a more immediate impact on organ shortage could 
be achieved by improving our current mechanisms for organ 
recovery and the management of potential donors. 
ORGAN RECOVERY 
Standardized criteria for the determination of brain death wen: 
defined by the Ad Hoc Committee of the Harvard Medical 
School'o and have been the subject of a more recent report .• I 
The concept of brain death and the management of the brain-
dead donor are discussed in detail in Chapter 174_ 
Once a potential organ donor is identified, the multiple 
organ procurement process should be triggered. This starts by 
contacting the local organ procurement organization (OPO) as 
soon as the irreversibility of brain injury has been established. 
As of July 1. 1997. there were 54 OPOs and 280 transplant 
centers in the United States. These represent the largest organ 
procurement and transplant network in the world_ Most inten-
sive care units aCUs) have the telephone number of the 
local agency available. However. the telephone number and 
location of area OPOs can be obtained from UNOS. which has 
a 24-hour telephone hot line (800-355-SHARE)_ 
These OPOs, originally set up to organize the recovery of 
kidneys. now also coordinate the complex logistiCS of multipil' 
organ recovery and their distribution within a predetermined 
geographic area. They are also responsible for the payment of 
all charges incurred during the process of organ donation. 
ensuring that donor families are not billed for any of them. 
Once contacted. the local OPO sends a procurement coordina-
tor to the referring hospital. These coordinators perform a 
number of administrative and technical functions. covering 
every aspect of the donation process. On receiving a referral, 
they perform an evaluation and discuss organ donation with 
the potential donor's family. making sure the relatives have a 
complete and satisfactory explanation of the diagnosis of brain 
----------~------------- -------_._---------_ .. _ .• _-----_ .... _._-
death and a clear understandin~ of the organ procurement 
process. 
Families should be informed separately but as soon as possi-
ble after the irreversibility of the lethal brain dama~e has been 
established and should be given a clear explanation of the 
prognosis. This measure will give them time to accept the 
patient's death and allow them to deal with their grief. It is 
important to respect this phase. because it has been demon-
strated that consent for donation increases from 18% to 60% 
if the family is allowed to absorb the concept of brain death 
first and if the issue of organ donation is brought up later.' 
Religious beliefs about human life, the dead body, and life 
after death are important considerations for those involved in 
organ donation and transplantation. No major religion specifi-
cally prohibits organ donation. although in some situations 
there may be restrictions. Table 177-1 summarizes some of 
the major religious and cultural beliefs associated with organ 
donation and transplantation. zz Families may feel the need to 
discuss the matter with a church representative before making 
a decision. 
If the family decides to donate, a consent for donation form 
is supplied by the hospital or by the procurement coordinator. 
and it is completed and signed by the next of kin. In addition, 
the coordinator ensures that all medicolegal requirements are 
met, from adequate documentation of brain death in the chart 
to securing permission from the coroner when necessary. 
Medical staff privileges for the recovery teams are also ar-
ranged. Hospitals differ in their policies for granting such 
privileges. Some hospitals do not consider the organ procure-
ment a surgical procedure because a determination of brain 
death has been made. In this circumstance. temporary privi-
leges are not required for outside surgeons. 
At the same time, the procurement coordinator assumes 
control of three main activities: 
• Donor evaluation 
• Coordination of donor and recipient matching 
• Donor operation and organ preservation and shipment to 
the recipient'S hospital 
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The role of the coordinator in each of these is critical. because 
the most important issue in or~an procurement. once the 
decision to proceed has been made. is to have someone 
who "directs traffic." maintaining clear lines of communication 
between the members of the different teams involved. A lack 
of communication at this point can disrupt donor care and 
compromise organ stability. Therefore. the needs and proto-
cols of the individual teams should be discussed in detail 
before any donor surgery begins. If possible. the logistic ar-
rangemerns between teams should be expedited so that no 
time constraints are placed on the host team. On the other 
hand. the host team must be tolerant because different organs 
often have to be flown to distant parts of the country, and 
some recipient surgery may be quite complex and time-con-
suming. To facilitate matters. the host team should make 
available basic information on the donor to expedite the evalu-
ation by the visiting teams (Fig. 177-2). 
DONOR EVALUATION AND 
MANAGEMENT 
There are few absolute contra indications to organ donation, 
and they can be grouped into three broad categories: 
1. Severe trauma. 
2. Malignancy outside the central nervous system (CNS). 
3. Active infections. 
Trauma refers only to major injury to the organ itself and 
does not preclude donation of those organs not affected. Even 
in the case of a major trauma. however. the final decision to 
use or discard the organ should be made only after surgical 
examination of the donor and careful examination of the 
organ's anatomy. In the case of a liver trauma, for example, 
many orgal1s' can be saved if the donor team is experienced 
in liver surgery. Minor. and even major, parenchymal lesions 
can be repaired in situ. and the vascular anatomy can be 
precisely determined during the final preparation of the organ. 
Techniques of transplantation of liver segments have been 
TABLE 1n-1. Major Religious and Cultural Beliefs Associated with Organ Donation and Transplantation 
Group 
Amish 
Baha'i 
Baptist 
Buddhist 
Christian Science 
Episcopal 
Evangelical Covenant 
Greek Orthodox 
Gypsies 
Hinduism 
Islam 
Jehovah's Witness 
Judaism 
Latter-day Saints 
(Monnon Church) 
Protestant 
denominations 
Society of Friends 
(Quakers) 
Roman Catholic 
Unitarian Universalist 
united Methodist 
Donation 
Reluctant if transplant outcome uncertain 
Acceptable 
Individual decision 
Individual decision 
Individual decision 
Encouraged 
Encouraged 
Acceptable (althOUgh not for research) 
Against 
Individual decision 
Acceptable (organs of Moslem donors must be 
transplanted immediately. and not stored in 
organ banks) 
Individual decision (not encouraged) 
Generally encouraged 
Individual decision 
Individual decision 
Individual decision 
Encouraged 
Acceptable 
Encouraged 
Transplantation 
Acceptable for the well-being of the candidate 
Acceptable 
Acceptable 
Buddha's teachings on the middle path (Le .. the avoidance of 
extremes) could be applicable to this 
Individual decision 
Encouraged 
Encouraged 
Acceptable for the well-being of the candidate 
Against 
Individual decision 
Acceptable 
May be considered acceptable (organs should be completely drained 
of blood before transplantation) 
Encouraged 
Individual decision 
Acceptable 
Individual decision 
Acceptable 
Acceptable 
Acceptable 
.
.
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described and successfully used. panicularly in pediatric pa-
tients. These techniques may be used to rescue a liver panially 
damaged by trauma. 
Malignancy, other than priIriary CNS tumors, is an absolute 
contraindication to organ donation, 
The presence of active infectiOns is an exclusionary crite-
rion that deserves close attention, Systemic sepsis, active tu-
berculosis, viral encephalitis, and Guillain-Barre syndrome are 
contra indications to organ donation, as well as active hepatitis 
or the presence of the hepatitis B surface antigen, Past infec-
tion with the hepatitis B virus (HBV), as evidenced by the 
presence of antibodies, was not considered a contraindication 
to organ donation until recently, Early in 1995, a study showed 
the transmission of hepatitis B in eight of 13 liver recipients 
(negative for HBV infection before the liver transplant) trans-
planted with livers from hepatitis B core antibody-positive 
donors.'l Our policy at the Pittsburgh Transplantation Institute 
is to use these donors only for hepatitis B core antibody-
positive recipients, 
Whether organs should be used if the donor has hepatitis 
C antibodies has been the subject of controversy in the past 
few years, as there is evidence of hepatitis C virus (HCV) 
transmission after transplantation. I. However, the organ shon-
age is so severe that the use of HCV antibody-positive donors 
must be seriously considered, at least for life-saving organs 
such as the liver, hean, and lungs," Obviously, for active 
disease to be ruled out, a prospective HCV antibody-positive 
donor absolutely requires a frozen section examination of the 
liver before implantation. 
The human immunodeficiency virus (HlV) has greatly af-
fected the field of transplantation. After the screening enzyme 
immunoassay became available in March 1985, a number of 
positive kidney, hean, and liver recipients were quickly re-
poned,l<> However, the extent of the problem was clearly 
defined only after a large study of 1043 transplant patients 
was completed at the University of Pittsburgh. It was found 
that, overall, 1.7% were positive for HlV, with the incidence 
in liver transplant patients being 2.6%, Only a third of these 
patients were positive before the transplantation, as deter-
mined by testing stored pretransplant sera. I" Donors who test 
positive for HlV antibody are now automatically rejected. 
Prospective donors should also have a Venereal Disease 
Research Laboratory (VORL) test as well as cytomegalovirus 
(CMV) titers, determined as soon as possible. TIle significance 
of a positive VORL test is difficult to ascenain, but it is our 
practice to treat recipients of VORL-positive donors with a 
course of benzathine penicillin. The CMV status of the donor 
has prognostic significance regarding the incidence and sever-
ity of subsequent CMV infections. Recipients of organs har-
vested from seronegative donors have a lesser chance of devel-
oping a CMV iniection, regardless of their own serologic 
status. 1M. 1') Epstein-Barr virus and varicella-zoster virus (VZV) 
are not pan of the routine donor viral screening. TIle only 
situation in which these viruses become relevant is when the 
donor has active disease related to them (infectious mononu-
cleosis or systemiC VZ;V infection), In these cases, organ dona-
tion should not be considered. 
Donors with infections under control or those affecting 
organs not specifically considered for donation (i.e .. an ab-
dominal organ donor suffering from pneumonia) may still be 
suitable, Children who die as a result of bacterial meningitis 
related to Haemopbiius injillenzae or Neisseria meningitidis 
can still be considered for donation if the organism and its 
sensitivity are known beforehand. 
Prolonged organ ischemia related to severe hypotension or 
cardiac arrest might represent a contraindication to donation. 
However. it is the policy of the Pittsburgh Transplantation 
Institute to Critically evaluate all donors. including those with 
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cardiac arrest and prolonged cardiopulmonary resuscitation 
(CPR). In fact, many of these donors have been found accept-
able by post-CPR physiologic and biochemical criteria, and 
their organs have been successfully transplanted. 19. }O 
Other patients who may not be acceptable as donors are 
those with a long-standing history of diabetes mellitus, hyper-
tension, and cardiac or peripheral vascular disease. Again, 
however, the donor and organ viability should be assessed on 
a case by case basis. A patient who is not acceptable as a 
hean or lung donor might still be an excellent abdominal 
organ donor. Sometimes the suitability of individual organs 
can be assessed only after direct exan1ination by the donor 
surgeon at the time of procurement. 
The donor's age deserves special mention, The chronologic 
age is less imponant than the physiologic age in assessment. 
For some organs, age may not be an imponant limiting fac-
tor. 1HZ We have successfully used livers from donors as old 
as 75 years. In 1985, Popperjj dedicated an extensive review 
to the aging of the liver. According to his study, the liver's 
great functional reserve, its regenerative capaCity, and its large 
blood supply are the key factors in its delayed aging compared 
with other organs. Based on these considerations, it has long 
been thought that the liver is less affected than other organs 
by senescence.;!. .u However, the demonstration that satisfac-
tory livers can be obtained from donors well into the seventh 
decade of life or beyond was followed by a flurry of confirma-
tory repons, countered by descriptions of degraded results 
using geriatric livers. 
Less has been written about the effect of the donor's sex 
on outcome of liver transplantation. Extensive literature, sum-
marized by Neuganen and Silbiger,'· shows poorer results 
with kidney allografts from female donors. 
We have examined the effects of donor age and sex on the 
outcome of a consecutive series of 462 liver transplants, 
which included the use of ';4 donors aged 60 years or older. 
Nine other donor variables and eight recipient variables were 
also analyzed, with the endpoint of the analysis being graft 
fatlure (defined as either patient death or retransplantation). 
Graft failure was Significantly associated with donor age and 
donor sex. The etlect of donor age was evident only when 
the donors were aged 4'; years or older. Livers from female 
donors yielded significantly poorer results, with the 2-year 
graft survival of the female to male combination being 55%, 
female to female 64%, male to male 72%, and male to female 
"78%.'1' 
We believe that older female donors E~SM years) are ques-
tionable for liver procurement because in them the adverse 
effects of age and gender are at least additive. Because of the 
current organ shonage crisis, we believe that these livers 
should still be used, but under circumstances that are adjudi-
cated on a case by case basis. For example, many liver trans-
plant centers in Nonh America and in Europe exclude from 
recipient candidacy patients who are HIV-positive, HBV carri-
ers with evidence of deoxyribonucleic acid (DNA) replication. 
and others with risk factors that predictably degrade patient 
and graft survival. TIlese patient categories would cenainly be 
better helped by receiving geriatric temale livers rather than 
being automatically excluded from transplantation. Table 
177 - 2 shows the age guidelines for individual organs used in 
our institution. In general. it is rare to tind a suitable hean or 
lung allograft from donors older than 60 years of age because 
of the increased incidence of coronary artery disease and 
chronic pulmonary disease. 
In summary, given the enormous need for organs and the 
few criteria that absolutely disqualify a potential donor, the 
local OPO should be contacted in vinually every case. Figure 
177 - 2 shows (he data collection tllrm used by (he Center tor 
Organ Recovery and Education, which is the organ procure-
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TABLE 177-2. Age Guidelines for Organ and Tissue Donation 
Used at the Pittsburgh Transplantation Institute 
OrganITissue Age (yr) 
Heart ,;;60 yr* 
Heart-lung ,;;60 yr* 
Lung ,;;60 yr* 
Kidney 1 month-75 yr* 
liver ,;;75 yr* 
Pancreas ,;;65 yr* 
Intestinet 
Bone 15-65 yr 
Bone marrow ,;;75 yr 
Cornea 1-65 yr 
Skin 15-65 yr 
Heart valve ,;;55 yr 
'Donors beyond these age limits could be accepted on the basis of the 
individual organ function. Female donors aged 66 years or older are question-
able for liver procurement because in them the adverse effects of age and 
gender are at least additive. 
tNo age limits have been set for intestinal donors. Intestines should be 
available from most organ donors and are always evaluated on an individual ba-
sis. 
ment agency for western Pennsylvania. southern New York. 
and West Virginia. ll1ese data should be promptly faxed to 
those involved in the evaluation process. 
Individual Organ Assessment: 
Abdominal Organs 
The criteria used to determine the suitability of kidneys are 
very flexible. As shown in Table 177-2, a kidney donor can 
be between 1 month and 75 years of age. Serum creatinine 
and blood urea nitrogen (BUN) are used as markers of donor 
renal function and should be normal. Obviously. donors with 
chronic renal disease are not considered for kidney donation. 
However, patients with transient creatinine and BUN eleva-
tions related to dehydration. hypotension. or both are not 
excluded from kidney donation if the BUN and creatinine fall 
after appropriate volume correction. 
Attempts at predicting liver allograft function after trans-
plantation based on donor information have met with little 
success. The diverse literature devoted to the topic is testi-
mony to our lack of a clear understanding, one that can 
translate into well-informed decision making during donor 
evaluation. ".1'--1(, As a rule, the donor should have normal or 
near-normal serum aspartate transaminase (ASD, serum ala-
nine transaminase (ALD, bilirubin. and prothrombin time, but 
we have successfully used livers from donors with AST and 
ALT that were 10 times greater than the upper limit of normal. 
The important parameter is not an isolated AST or ALT value, 
but the trend established since the ICU admission .• C The biliru-
bin can be elevated as a result of massive blood transfusions 
used during the resuscitation of a shocked patient. A history 
of hepatitis or alcoholism is certainly a warning sign but does 
not preclude the use of the liver. In general. in the case of a 
marginal liver donor. the intraoperative assessment by the 
donor surgeon is the best single piece of information. 
l1lere is only one absolute exclusion criterion in the evalua-
tion of a pancreas donor: a history of diabetes mellitus. Amv-
lase elevations have been seen in as many as 39°1., of pancreas 
donors without any evidence of pancreatitis. and thus isolated 
hvper.lmylasemia does not contraindicate the use of the pan-
creas .• X TIle serum glucose may be falsely elevated in donors 
receiving steroid therapy or as a result of decreased circulat-
ing insulin. ,., 
Intestinal tr.lnsplantation is emerging as a valuable modality 
for the treatment of patients with intestinal failure. Early in 
1993, UNOS formed a subcommittee responsible for systema-
tizing the listing of recipients. helping identify suitable donors, 
and establishing guidelines for the equitable allocation of intes-
tinal grafts at both the local and national levels. Because of 
the time constraints. it is impossible to perform a functional 
assessment of the donor bowel. Relatively young age, hemOdy-
namic stability, and donor-recipient size match are the critical 
parameters used in evaluating an intestinal donor. so At our 
institution, preference was initially given to infant and juvenile 
donors with stable hemodynamics. However, the age range 
has gradually expanded, providing the donor is stable and 
receiving mininlal vasopressor support (=::; 10 lLg/kg - '/min - , 
of dopamine). Size matching is always given special consider-
ation. The majority of intestinal transplant recipients have 
undergone extensive intestinal resections, leading to a signifi-
cant reduction in the size of the abdominal cavity. Therefore, 
donors are chosen who weigh 15% to 40% less in body weight 
than the selected recipients. so 
Individual Organ Assessment: 
Thoracic Organs 
Aside from a negative history of cardiac disease and a normal 
chest x-ray film, the donor should have a normal heart physical 
examination and 12-lead electrocardiogram. However, a num-
ber of electrocardiographic changes may be detected in brain-
dead patients, which do not preclude thoracic organ 
donation.S!." A brain-dead patient who is able to maintain a 
systolic blood pressure greater than 90 mm Hg with a dopa-
mine requirement less than 10 1Lg/kg - '/min -, is considered a 
suitable candidate for heart donation. I~K ,. Cardiac isoenzymes 
are recommended in the case of chest trauma, to rule out 
myocardial contusion. and when the potential donor has sut~ 
fered a cardiac arrest or prolonged hypotension. In male do .. 
nors older than .35 years of age, the incidence of coronary 
artery disease increases, especially with risk factors such as 
hypercholesterolemia, a family history of heart disease, and a 
history of smoking. Coronary angiography may be helpful in 
the evaluation of high-risk and older donors. but it is not 
routinely required and most hospitals find the logistics of 
performing it prohibitive. TIlerefore, a decision must be made 
based on a cardiologic consultation. evaluating the history. 
electrocardiogram. and echocardiogram. 
As is the case for the liver. and because of the severe 
shortage, it is prudent, even in high-risk donors, for the heart 
to be examined on the operating table following sternotomy. 
Visualizing and palpating the coronary arteries provides a 
significant amount of information with respect to the inci-
dence of coronary artery disease. If plaques are felt along the 
left main coronary artery or left anterior descending artery. 
the heart, in most cases. is not suitable for transplantation. In 
extreme cases of a sick reCipient, however, the transplantation 
team may decide to use this heart. Isolated cases of coronary 
artery bypass being pertormed at the time of transplantation 
have been reported. Reports exist of cases of isolated mild 
coronary artery disease in which the donor allograft functions 
well. with no increase in earlv mortality. 
Transesophageal echocardi~graphy has been demonstr.lted 
to be an important adjuvant in the evaluation of a potential 
cardiac donor. Severe cardiac hypertrophy. valvular defects. 
and global myocardial dysfunction or s~mental wall abnor-
malities have been diagnosed in what appeared to be other-
wise reasonable cardiac donors. At this time. limited informa-
tion is available about the use of such hearts. In most cases. 
it is prudent to avoid the use of a hean with demonstrJted 
wall-motion abnormalities." In gcneral. minor ch:lOges in the 
electrocardiogr.lm or echocardiogram. localized infection. , .. 
-,. 
transitory hypotension. brief cardiac arrest. and thoracic 
trauma do not contraindicate heart donation. The importance 
of donor-recipient weight mismatch greater than 20% is criti-
cal only in the face of high pulmonarv vascular resistance. [n 
carefully selected donors, survival after transplantation with a 
donor between 40 and 55 years of age is no different than 
that observed in the case of younger donors. ,- As the limits 
for donor selection are extended. it becomes more evident 
that it is safe to extend donor age up to 'i5 to 60 years and 
ischemic time longer than 4 to 5 hours."-'" 
The presence or absence of cardiac or cardiopulmonary 
arrest in itself is not a contraindication to the use of a heart 
for transplantation. Especially in the pediatric population, it 
has been found that even in donors who have undergone 
extended CPR (up to 125 min), as long as cardiac function at 
the time of cardiectomy is normal. there does not appear to 
be an increased risk for performance of the heart or survival 
of the recipient after transplantation. 
All of the selection criteria mentioned in the case of a heart 
donor also apply to heart-lung or isolated single or double 
lung donors. In addition, a donor is not acceptable for lung or 
heart-lung donation when there is a history of heavy smoking, 
chronic lung disease, or pulmonary aspiration. The height, 
Weight. and chest circumference of the heart-lung donor 
should closely match those of the recipient. A number of 
physiologic parameters can be used when assessing a lung 
donor. including the partial pressure of arterial oxygen/frac-
tion of inspired oxygen (Pao,/FIOz) ratio (2:250 mm Hg) and 
peak airway pressure « 30 em H20 with 1 <; mljkg of tidal 
volume and <; cm H,O of pOSitive end-expiratory pressure 
[PEEP]).',I-'" Aspiration pneumonia is frequent in the brain-
dead patient. and thus the character of the sputum is a critical 
piece of information. The role of bronchoscopy is still being 
debated: it is considered mandatory by some authors,'" 
whereas others believe it is indicated only when there is a 
question of foreign-body aspiration or to obtain sputum for 
Gram's stain and culture. ," Bronchoscopy, however, provides 
important culture information to guide appropriate antibiotic 
therapy after transplantation. If frank purulence is noted on 
bronchoscopy, the lungs are not suitable. However, one lung 
mav be salvaged for transplantation from a set in which one 
appears to be more infected than the other. 
COORDINATION OF DONOR AND 
RECIPIENT MATCHING 
Once the coordinator finishes the donor evaluation, there are 
still many hours of intense work before completing the pro-
cess. After obtaining the appropriate consent. therapeutic ct~ 
t(lrts should be geared to protect the donated organs until the 
actual retrieval b accomplished. Their integrity should be 
maintained by optimal organ perfusion. avoidance of further 
damage, and subsequent removal and preservation with mini· 
mal ischemic injury. Care of the donor during organ procure· 
ment, therei()re. requires a continuation of the intensive care 
that was provided bctore brain death was declared. followed 
by a preCise surgical procurement procedure. W1lereas in 
the 1')'"'Os and early 1980s donor management mainly. if not 
exclusively. addressed kidney function, the patient now must 
alwa\'s be approached as a multiple donor, and this can pre· 
sent a real challenge to the physician managing the case. 
The physician should keep the patient hemodynamically 
stable with optimal organ perfusion and oxygenation. This is 
not eaw because of the loss of many body rct\exes and the 
dr-.lmatic changes in the hormonal milieu.'" Several studies 
have shown a significant rcduction of cortisol.'"' insulin.'"' and 
thyroid hormones." ,",.-CI .. \bout 'iO"{, 10 -OOt, of br.lin-<..iead 
p;;tiems suiter from diabetes insipidus." ., .\ number of proto-
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cols that call for the use of hormones such as triiodothyronine. 
cortisoL or insulin during donor management have given con-
flicting results:" '2 ,,- 6<) -0. 7' 
The details of donor management are provided in Chapter 
174 and are not repeated here. We stress only a few points 
we believe are important. Adequate perfusion should always 
be maintained while keeping the use of vasoactive drugs to a 
minimum. This may require the administration of several liters 
of fluid to obtain adequate filling pressures. Replacement ther-
apy with fresh frozen plasma, platelets. and cryoprecipitate 
may be used if a serious bleeding diathesis is present. How-
ever, even if fibrinolysis is suspected, E·aminocaproic acid 
should be avoided because it can induce microvascular throm-
bosis in the donor organs. 
During this phase, the procurement coordinator asks local 
transplantation programs about their needs for organs. Under 
the current system, local programs have first priority, and only 
when organs are not used locally are inquiries made at the 
regional and national levels. An exception to this rule is when 
a prospective kidney recipient who resides in another region 
is found to have a so-called six-antigen match. These kidneys 
have to be sent away, with the receiving transplantation center 
"paying back" at a later date. Organ allocation is a very compli-
cated and controversial subject, and what system should be 
used is presently being debated.1O As of this writing, amend-
ments to the National Organ Transplant Act (NOTA) are being 
discussed in Congress. and it is not clear what changes will 
be implemented. 
A point system tor renal transplantation was developed in 
Pittsburgh in 1985. Credit points were given to renal trans-
plant candidates for time waiting, quality of antigen match, 
degree of immunologic sensitization, medical urgency, and 
logistic considerations of getting the donor organ and the 
reCipient together within the time limitations of safe organ 
preservation. TIle system began in western Pennsylvania on 
January 1, 1986." Although initially adopted by UNOS on 
November I, 1987, the point system never went into effect 
at the national level because of difficulties encountered in 
reconciling it with a myriad of local interests. A similar point 
system was developed for liver transplantation. having been 
in place in Pittsburgh since Januarv 1987. Our experience 
with organ allocation based on point systems. in which organs 
go to those who have been waiting longer or are sicker, has 
been most favor-.lblt:. lo II Gr-dft and patient survivals have not 
suffered by giving organs to sicker or older patients. At the 
Sanle time, our observations provide some assurance that the 
concepts of equitable access and efficient use of a scarce 
societal resource are not mutually exclusive. 
Although human leukocyte antigen (HLA) matching is not a 
critical issue for extrarenal organs, we routinely perform HLA 
typing on all extrarenal organs, a practice at variance with 
what most other institutions do in the United States. Although 
it is expensive. we consider it important because it allows us 
to determine the presence of microchimerism in the reCipient, 
information that mav be extremelv useful in the future when 
,!t:ciding how to manage the immunosuppression.7• 
When the reCipients t(lr all the abdominal and thoracic 
organs are identified. an oper-.ning room (OR) time in the 
donor hospital is arr-.lnged. The procurement coordinator con-
tacts the recipient institutions to arrange tor the simultaneous 
arrival of all the harvesting teams. Kidneys have been pro-
cured bv local teams t(lr many years and shipped if they were 
not used locally. Today. a similar pr-.lcticc is being adopted in 
tile United Statcs tl)r other organs, particularly livers." 
TIle intestinal donor should receive intravenous ampicillin 
and cet(ltaxime at the appropriate doses when first evaluated 
and e\'cn' () hours after that. The last dose is gi\'en in the 
OR at the time 01 harvesting. molyDE~tl1yDlene glycol-electrolvte 
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solution (GoLYTELY) is administered through the nasogastric 
tube to flush the intestine. The total amount ranges from 250 
to 2000 mL, depending on the recipient's body size (250 mL 
in the infant and 2000 mL in the adult), and the administration 
rate is 10 to 30 mL/min. After the intestinal flushing, an 
antibiotic mixture that includes polymixin E (100 mg), tobra-
mycin (80 mg), and amphotericin B (500 mg) is given through 
the nasogastric tube every 4 hours until procurement. In 
pediatric donors, the doses are halved, whereas infants receive 
only one tourth of the dose. Newborns receive no intestinal 
preparation. If preharvest flushing cannot be performed, this 
is done after procurement, using cold lactated Ringer's solu-
tion. Polymixin B or kanamycin can be substituted for poly-
myxin E, if the latter is not available at the donor hospital. 
MULTIPLE DONOR OPERATION 
Anesthesia 
The donor operation can be time-consuming, and the role of 
the anesthesiologist is very important, especially if we com-
pare the multiple organ procurement that is now usually 
performed with those carried out in the past, when the kid-
neys were often the only organs removed. A complete review 
of the anesthetic aspects of organ donation was recently pub-
Iished,-" and we will restrict ourselves to its salient points. 
The goal of medical management during organ procurement 
is to avoid ischemic organ damage by optimizing organ perfu-
sion. Therefore. care of the donor is a continuation of the 
intensive care that was provided betore brain death (see Chap-
ter 174). The most important issue is the clear communication 
between the members of the procurement team because the 
surgical procedure and procurement protocol may differ de-
pending on the procurement team and the specific organ. For 
the preoperative evaluation of the donor, the anesthesiologist 
should review the medical and surgical histories, including 
the cause of brain death, condition and supportive measures 
of vital organs, drug allergies, and medications. Cardiopulmo-
nary function is assessed by means of the hemodynamic pro-
file, reqUirement of inotropic support. efficiency of gas ex-
change, degree of ventilatory support. chest radiograph, 
electrocardiogram, arterial blood gas tensions. and acid-base 
state. Renal function is evaluated by urine output, BUN, and 
serum levels of creatinine and electrolytes. Hepatic function 
is evaluated by AST, ALT. and bilirubin. and pancreatic func-
tion is evaluated by blood glucose level and serum amylase, 
Hemoglobin concentration and the blood type of the donor 
are identified to prepare blood products. In addition, the 
validity of brain-death certification, consent from family mem-
bers. and permission from the coroner are verified. The transi-
tion from the ICU to the OR is a crucial period, and the donor 
is continuously monitored, ventilated. and treated. 
Intraoperative care of the donor is essentially similar to 
that of other critically ill patients undergoing major surgery, 
although management of pathophysiologic changes unique to 
the donor should be clearly understood. In general. eqUip-
ment and medications routinely available for general anesthe-
sia are satisfactory tor the management of donors. However, a 
volume \'entilator may be needed for donors requiring high 
levels of PEEP or airway pressure. TIle OR should be kept 
warm. and a warming blanket and blood warmer are neces-
sarv ro prevent hypothermia. A large volume of crystalloids 
and colloid solutions (e.g" 5% albumin, plasma protein frolc-
tion. or hetastarch) and five units of packed red blood cells 
should be prepared. TIle electrocardiogram is monitored. pret~ 
erablv using lead V" to detect arrhythmias or myocardial 
ischemia. particularlv in heart donors. mood pressure is moni-
rored by an indwelling catheter in the roldial arten' or brachial 
artery. The femoral artery cannulation is avoided because the 
aorta will be cross-clamped, Central venous pressure (CVP) 
monitoring is essential. -, and a pulmonary arterial catheter is 
useful in unstable donors, Two-dimensional transesophageal 
echocardiography may be used to assess preload and cardiac 
contractility in unstable heart donors. Urine output and body 
temperature are monitored. and all or some of the following 
laboratory tests may be needed: hemoglobin and hematOCrit, 
arterial blood gas tensions and acid-base state, serum electro-
lytes, ionized calcium. lactate, and blood glucose level. 
General anesthetic agents are required to blunt sympathetic 
response that occurs during surgery.78 This so-called mass 
reflex is caused by neurogenic vasoconstriction and stimula-
tion of the adrenal medulla by the spinal reflex arc and mani-
fests as tachycardia hypertension, perspiration, and involun-
tary movements. These movements, also known as the 
Lazarus sign, which includes arm and hand movements to-
ward the body, can be disturbing to those involved in the 
organ recovery, and muscle relaxants should be administered 
ahead of time, 
Isoflurane is the agent of choice because the degree of 
myocardial depression is less than with other inhalation 
agents. Halothane is avoided in liver donors because hepato-
toxicity may be a concern in the presence of potential hepatic 
ischemia. Entlurane is avoided in kidney donors because it 
increases the blood level of inorganic fluoride. Short-acting 
narcotiCS, such as fentanyl (5 to 10 f.l.g/kg), may be used in 
hemodynamically unstable donors. In addition, muscle relax-
ants (pancuronium bromide, 0.05 to 0.1 mg/kg, or vecuro-
nium bromide, 0.05 to 0.1 mg/kg) are required to provide 
satisfactory abdominal muscle relaxation and to abolish invol-
untary movements. Other pharmacologic interventions in-
clude systemic heparinization (300 to 500 Ulkg) before cannu-
lation of the aorta, mannitol (0.25 to 0,5 g/kg), and furosemide 
(40 mg) to induce diuresis betore division of the renal pedicle 
and prevent ischemia-induced acute tubular necrosis. ~9-"D 
Alpha-adrenergiC receptor blockers, such as phenoxybenza-
mine, may be used to promote renal vasodilation and prevent 
vasospasm."' However, these blockers are not recommended 
in multiple organ procurement because their effects on other 
organs are unknown. ProphylactiC administration of antibiot-
ics such as broad-spectrum cephalosporins is recommended 
by some centers,"'"' although its efficacy is controversial:-"' 
Specific goals of ventilatory care are to maintain a Pao, 
between 70 and 100 mm Hg, an oxygen saturation of arterial 
hemoglobin greater than 95%, and a partial pressure of arterial 
carbon dioxide within the range of 35 to 45 mm Hg to avoid 
pulmonary complications. In hypothermic donors, a mild res-
piratory alkalosis (pH 7.4 to 7.5) may be preferred to improve 
tissue perfusion,""'"' This goal frequently is achieved by venti-
lating with a tidal volume of 10 to 15 ml/kg, a respiratory 
rate of fewer than 20 breaths/min, flO, of 30% to 40%, and a 
low level of PEEP «5 cm H,O). However, when pulmonary 
complications intertere with gas exchange, the tidal volume is 
increased up to 20 mL/kg, the respiratory rate is increased up 
to 20 breaths/min. and the PEEP is increased up to 10 cm H,O. 
In general, an increase in FlO, is preferred to an excessive 
tidal volume and high PEEP to maintain venous return and 
splanchnic blood flow. 
The goal of circulatOry care is to preserve perfusion of all 
organs that are to be procured by maintaining systolic blood 
pressure between 100 and 120 mm Hg, with a CVP less 
than 10 cm H,O and minimal vasopressor support.' ..... · "" 
Hypotension (systolic blood pressure < 80 mm Hg or mean 
arterial pressure < -lO mm Hg) is associated with an increased 
incidence of acute tubular necrosis and nonfunction of the 
donor kidnevs'" 'n as well as poor function of the liver.''' 
However. maintaining a satisfactory hlood pressure is difficult 
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to achieve at times because of altered circulatory physiology 
in the brain-dead donors. Preload frequently is decreased be-
cause of blood loss, vasomotor paralysis. diuretic therapy, or 
diabetes insipidus. Tachycardia, bradycardia, and arrhythmias 
caused by massive sympathetic discharge are not unusual. and 
myocardial contractility frequently is impaired by myocytol-
ySis, coronary spasm, and reduction of myocardial energy 
storage."' Afterload may be increased by excessive sympa-
thetic tone or decreased by vasomotor paralysis. 
Intravascular volume is adjusted with the guidance of the 
CVP « 1 0 cm H20). Fluid deficit is corrected with the infu-
sion of a balanced electrolyte solution (e.g., lactated Ringer's 
solution) or a colloid solution (5% albumin or hetastarch).94 
Urine output and insensible losses are replaced by a hypotonic 
solution with glucose (e.g., 5% dextrose in 0.45% sodium 
chloride [NaCl], 1 mUkg - l/hoUr- I). Adjllstment of intravascu-
lar volume may decrease the need for vasopressors in many 
casesI9~ but acute volume expansion may increase myocardial 
oxygen consumption, congestive heart failure, arrhythmias. 
and the need for inotropic support because the compliance 
of the heart is decreased in most donors.91 Excessive urine 
output (>200 to 250 mUhour) is replaced by a hypotonic 
electrolyte solution with supplementation of potassium chlo-
ride (KCI. 20 mmol/L). When hypotension persists even after 
adequate volume replacement. vasopressors may be required. 
Dopamine (2 to 5 jJ.g/kg-l/min- 1 and up to 10 jJ.g/kg- '/ 
min - I) is the first choice to improve cardiac contractility. 
Other inotropes include dobutamine (2 to 10 jJ.g/kg-l/min -I) 
and isoproterenol (0.1 to I jJ.g/kg- I/min - I), but these drugs 
may dilate peripheral vascular beds, decreasing blood pres-
sure. Alpha-vasopressors (phenylephrine, norepinephrine bi-
tartrate, or metaraminol bitartrate) are avoided because they 
may decrease splanchnic and coronary blood flow. 96_ 97 In 
addition. the oxygen-carrying capacity to the peripheral tis-
sues is improved by transfusion of packed red blood cells (l 
to 3 U) to maintain the hematocrit between 25% and 30%."" 
Severe cases of tachycardia and hypertension caused by the 
mass retlex may be controlled by the administration of general 
anesthetics. a beta antagonist, such as labetalol or esmolol. or 
a calcium channel blocker, such as verapamil.«' Occasionally. 
an a-blocker. such as hydralazine or sodium nitroprusside. may 
be given to reduce afterload. Supraventricular or ventricular 
arrhythmias are treated with conventional antiarrhythmic 
drugs. Circulatory arrest, which occurs in 10% of potential 
donors and in 66% of referred donors,99 is treated according 
to conventional circulatory resuscitative measures. If bradycar-
dia is a concern, a direct-acting agent, such as isoproterenol 
or epinephrine, is used because donors are unresponsive to 
centrally acting chronotropic drugs, such as atropine. 
Progressive hypothermia, which is seen in up to 86% of 
donors because of the loss of hypothalamic function. ~f results 
in sinus bradycardia, atrioventricular dissociation, and ventric-
ular arrhythmias. At a temperature lower than 28°C, prolonged 
PR and QT intervals and wide QRS complexes are replaced 
by T-wave inversion, ST-segment depression. and a rise of 
ventricular fibrillation. Other effects of hypothermia are a 
leftward shift in the hemoglobin-oxygen dissociation curve, 
an increase in blood viscosity, a decrease in splanchnic blood 
tlow and glomerular filtration. hyperglycemia. and metabolic 
and respiratory acidosis. Body temperature is kept within the 
normal r.mge (>35°C) by increasing the room temperature, 
infusing all fluids through a blood warmer. and using a warm-
ing blanket and a heated humidifier in the inspiratory limb of 
the ventilation circuit. 
Adequate diuresis (>0.5 mL/kg '/hour '. preferably I to 
I. <; mLJkg '/hour ') is important because urine output is an 
indirect indication of preload and a prognostic indicator for 
renal gr.lft and hepatic function. 100 111e administration of fluid 
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or dopamine may be effective in maintaining adequate renal 
perfusion and diuresis. However, a high dose of dopamine 
(>10 lJ.g/kg-l/min- l) may lead to acute tubular necrosis and 
nonfunction of the renal graft.90 For persistent oliguria, furose-
mide (l to 2 mg/kg) and mannitol (0.5 g/kg) may be adminis-
tered. Diabetes insipidus, caused by a nonfunctioning pituitary 
gland, results in polyuria, hypovolemia, and electrolyte imbal-
ance. Excessive urine output is replaced with a hypotonic 
solution (0.45% NaCI with KCl, 20 mmoVL), and supplemental 
antidiuretic hormone is administered to maintain urine output 
in the range of 100 to 250 mUhour. The synthetic analog of 
vasopressin, desmopressin acetate (DDAVP), is preferred (0.5 
to I U!hour) because of its long duration of action and a 
low pressor/antidiuretic effect ratio. 101 However, the pressor 
activity in excessive doses of DDAVP may increase the risk of 
acute tubular necrosis \02 and reduce hepatic blood flow. \03 
DDAVP increases the sensitivity to catecholafi1ines, 103 and cate-
cholamine doses should be reduced when DDAVP is given to 
the donor. Hyperglycemia is a complication of diabetes insip-
idus and is treated by an infusion of insulin (5 to 10 U). 
Metabolic acidosis caused by inadequate tissue perfusion 
may be compounded by respiratory acidosis. Because of po-
tential myocardial depression, metabolic acidosis is corrected 
by administration of sodium bicarbonate. When hyperna-
tremia is a concern, tromethamine, or trls(hydroxymethyl) 
aminomethane (THAM) may be used instead of sodium bicar-
bonate: 
0.3 mol THAM (mL) = body weight (kg) X 
base deficit (mmol/L) 
Electrolyte imbalances (hypernatremia, hypokalemia, hypo-
calcemia, hypophosphatemia, and hypomagnesemia) caused 
by fluid shifts and diabetes insipidus may result in arrhythmias 
and myocardial dysfunction. Hypernatremia and hypokalemia 
are treated by administration of a hyponatremic solution 
(0.45% NaCl) and KCI (20 mmol/L). Ionized hypocalcemia 
caused by large blood transfusions is corrected by the adminis-
tration of calcium chloride or calcium gluconate to preserve 
cardiac contractility. Hypomagnesemia is treated with magne-
sium sulfate (50 mg/kg), also to preserve myocardial contrac-
tilitylo. Glucose metabolism is relatively well maintained, al-
though hyperglycemia may occur as the result of a decreased 
level of insulin and as a complication of diabetes insipidus. 
Serum levels of triiodothyronine, insulin. and cortisol are low 
in animal models, and the administration of triiodothyronine 
improves hemodynamic stability by maintaining myocardial 
stores of energy and glycogen: however. the beneficial role of 
triiodothyronine is unclear in clinical settings." 68 
Coagulopathy may occur in organ donors. Dilutional coagu-
!opathy is caused by the shift of intravascular volume, con-
sumption coagulopathy may result from the release of tissue 
thromboplastin from injured tissues and the ischemic organs, 
and fibrinolysis results from intravascular coagulation or the 
release of tissue plasminogen activator from the ischemic 
tissues. Disseminated intravascular coagulation (DIC) has been 
reported in 80% of donors with head injury, Iii' but its clinical 
significance is unknown. Coagulation abnormalities are 
treated conservatively. 
Once cardioplegia is induced, no further supportive care is 
necessary. After cross-clamping of the aorta (the time is re-
corded by the procurement coordinator) (Fig. 177-3), me-
chanical ventilation and monitoring are discontinued and all 
cannulas are removed. The organs are swiftly removed in the 
following sequence: heart, lungs, liver, pancreas, intestine, 
and kidneys. No supportive care is needed for procurement 
of corneas or bones because these tissues tolerate a prolonged 
ischemia without significant injury. 
~-----------K--K-
Recovery Data Donor 10# 
Surgeons Renal: 
Assisting: ___________________ _ 
Hepatic: 
Cardiac: 
Heart/Lung: 
Pancreas: 
Coordi nators/Technicians (Tissue): 
In O.R. _____ AM Incision ____ AM Depart O.R. (0) ____ AM Depart O.R. (T) ____ AM 
PM PM PM PM 
Condition During Surgery (include: Blood Pressure, Urine Output, Complications, 
Comments) 
Operating Room Drugs (include dosage and time) 
Methylprednisolone: _____ _ Mannitol: _________ _ Furosemide: __________ _ 
Heparin: _________ _ Vasodilator: Blood Products ________ _ 
Antibiotics: __________ _ Others: ______________________________ _ 
Nephrectomy Data Hepatectomy Data Cardiectomy Data 
En Bloc: YIN In Situ: YIN Precool Start ________ Infusion Start: ________ _ 
Flush Sol'n: ____________ Vol: ___ Sol'nNol: _____________ SoI'nNol. _________ _ 
Final Flush (Sol'n Vol): Portal Flush Start: ______ Clamps Off: _______ _ 
Storage Sol'n: Sol'nNol: _________ ~C::;o:::l!!dK!ls~c:;h:=e:mK::Kia=_;q;im~e=-====== 
Aortic Flush Start: ______ Heart Lung Data 
Art Clamp: 
Flush Start 
Flush End: 
Warm Ischemia Time 
Clamps 011: 
Cold Ischemia Time 
R 
Single or Double Lung Data 
L 
Sol'nNol: -I-nf-u-.-io-n-S-ta-rt--(R ... )-_-_-:..-_-_-_-_-_ -_ -_-_ 
Final Flush (Sol'nNol) _____ Sol'nVol: ________ _ 
Clamps Off: _________ Infusion Start (L) _____ _ 
Cold Ischemia Time _____ SoI'nNol: ________ _ 
Anatomy: _________ Clamps Off: ________ _ 
Cold Ischemia Time 
Pancreas Data 
Infusion Start: ______________ _ Infusion Start: ________________ _ 
Sol'nNol. _____________________ _ Sol'nNol. __________________ _ 
Clamps Olf: _____________________ _ Final Flush; (Sol'nNol) ____________ _ 
Cold Ischemia Time __________________ _ Clamps Olf: ________________ _ 
Cold Ischemia Time ____________ _ 
Anatomy _________________ _ 
Renal Anatomy 
L D 
B,opsy Results: ____________________________________________ _ 
Organs and T,ssues Recovered (Check appropnate box and circle "T" for Transplant, "R" lor Research) 
o R·KI T/R 0 L-KI T/R 0 LI T/R 0 LU TIR 0 PA T/R 0 HR T/R 0 HV T/R 0 MV T/R 0 Bon •• T/R 
o BM T/R 0 Veins TiR 0 Skin T/R 0 Cornea T/R OINT T/R 0 Other T/R 
Figure 1n-3. Intraoperative data collection sheet used bv the Western Pennsylvania Organ Procurement Organiution, CORE (Center lor 
Organ l{ecovery and Education). (Courtesv of Brian Broznick.) 
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Donor Operation 
Before starting a multiple procurement. the different surgical 
teams must discuss the techniques and sequence they want 
to adopt. A detailed discussion of the surgical procedure is 
critical because, after aortic cross-clamping, time is of the 
essence. Everything should proceed as smoothly and expedi-
tiously as possible to minimize organ damage. The basic prin-
ciple of any donor operation is the core cooling of the organs 
to be removed. Cooling of a solid organ at the time of donor 
circulatory arrest was described for experimental liver trans-
plantation nearly 40 years ago. '0" Cooling was then promptly 
applied to kidney preservation in clinical transplantation, 1l~ 
and it still represents the single most important aspect of any 
organ preservation technique. The first solution used was 
chilled lactated Ringer's solution. replaced in the late 1960s by 
the so-called Collins' solution, characterized by an electrolyte 
composition close to the intracellular one. lOS TIlis solution 
was successfullv used for about 20 years until the introduction 
of the Universitv of Wisconsin solu"tion, fl~K 110 which extended 
the duration oi organ viability. The easiest way to achieve 
almost immediate internal core cooling of the donor organs is 
bv in situ infusion of the preservation solution. chilled to 4°C, 
at the time of the circulatory arrest. The remaining technical 
aspects of organ retrieval are secondary to this critical maneu-
ver. 
The surgical procedure for multiple cadaveric organ pro-
curement has undergone a progressive evolution. In 1984, 
when procurement of extrarenal organs was becoming more 
common. the Pittsburgh group'll published a technique that 
required a meticulous in vivo dissection of the donor organs 
and extensive manipulation of the abdominal viscera. A subse-
quent refinement of this technique was introduced in 1986. "2 
This improved technique is used today and is basically charac-
terized by a "no-touch en bloc removal" of the core cooled 
solid organs. TIle technical details of this oper.ltion lie outside 
the scope of this chapter. and we will only describe the 
major points. 
A complete midline incision is performed from the supr.l-
sternal notch to the pubis (Fig. 1""'7-4) (see Color Plate). As 
soon as the thoracic and abdominal organs are visualized. the 
procurement coordinator collects the first inti)rmation on the 
appearance of the donor organs and relays it to the local OPO 
so that it can be made available to the recipient teams. The 
aorta is then exposed and encircled either immediately above 
or below the diaphragm (Fig. 1""7-5) (see Color Plate). The 
Figure 177-4. Intcaopcr.1l1\,e phEFto~raph shEFwin~ the 
(otal midline incision uscd ti)r multiple procurement. (S<:e 
Color Plate.) (Courtesy of Andreis Stieber .. \ID.) 
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inferior mesenteric vein is encircled and cannulated for infu-
sion of the cold portal perfusate. The aorta is then dissected 
for 2 em at the level of the origin of the inferior mesenteric 
arterY. which is tied and divided. The aorta is encircled at this 
level' and prepared for cannulation. Figure 177-6 shows the 
donor inferior mesenteric vein and the infrarenal aorta cannu-
lated for the cold perfusate (see Color Plate). The common 
bile duct is tied distallv and transected close to the upper 
margin of the duodenu~K and the gallbladder is incised and 
washed free of bile to prevent autolysis of the mucosa of the 
biliary tract. 
The arterial anatomy of the liver should be carefully exam-
ined for possible anomalies. Prior knowledge of any anomaly 
is helpful in preventing mistakes during organ removal. At this 
point. the basic initial dissection is completed (Fig. 177-7) 
(see Color Plate) and the thoracic team prepares the chest 
organs for removal. The pleural spaces are opened widely 
after initial mediastinal dissection. Very little initial dissection 
is done around the inferior and superior vena cava and aorta 
other than to place sutures for the expected cannulation of 
the aorta for cardioplegia or the main pulmonary artery if the 
lungs are being harvested as well. The lungs are quickly 
examined through the pleural spaces, and little dissection is 
required thereafter. It should be noted that the donor's heart 
has continued beating spontaneously and maintained circula-
tion of all organs. 
As soon as the thoracic team completes its dissection, 300 
to 500 U/kg of heparin is given intravenously, and the aorta is 
cannulated after ligating it distal to the inferior mesenteric 
artery (see Fig_ 177-6). The thoracic team then occludes the 
superior vena cava. and the aorta is simultaneously clamped 
proximal to the innominate artery and just above or below the 
diaphragm (Fig. 177-8) (see Color Plate). The cold infusion is 
started. the inferior vena cava is vented. and the heart is 
separately perfused with cold cardioplegic solution. The heart 
is removed first. If the lungs are being harvested simultane-
ously, cold flush is started through the pulmonary artery, 
venting the solution through the left atrial appendage. 
Once cardioplegic solution has been administered, the aorta 
is transected. and the rest of the lung perfusion solution is 
allowed to drain through the open aorta. Mediastinal dissec-
tion is then carried out. removing the lungs and heart en bloc 
if the block is to be used lor a heart-lung transplant. The more 
common situation is one in which the heart is harvested by 
one group and the lungs are used for separate transplants. In 
this situation. once the cardioplegia and lung perfusion have 
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Central tendon 
at alte of 
previous fusion 
with DericarctiUl 
Figure 177-6. Intraoperative photograph showing cannulas for cold 
perfusion inserted into the dissected donor interior mesenteric vein (IMV) 
and the infrarenal aorta (IA). (See Color Plate.) (Courtesy of Andreis Stieber. 
~aKF 
Figure 177-5. The aorta is 
dissected and encircled just above 
(or. alternatively. just below) the 
diaphragm. L. triangular lig. = 
left triangular ligament; encircled 
upper abd. aorta = encircled 
upper abdominal aorta; C.A. = 
celiac axis; S.M.A. = superior 
mesenteric artery; I.M.A. = 
inferior mesenteric artery. (See 
Color Plate.) 
1 
\ 
-~""K; 
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Portal v. 
R. gastric 
Gastroduodenal 
Common bile 
duct 
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Thoracic aorta 
encircled 
for cross-clamp y.:J Preservation 
fluid 
Upper abdominal 
aorta encircled 
L. gastric a. 
a. 
Splenic v. with 
cannula 
Sup. mesenteric v. 
encircled 
Figure 177-7. Uver hilar dissection. transection of the common bile duct. and incision of the gallbladder fundus to prevent autolysis of the 
mucosa of the biliary tract. In this drawing. the splenic vein is cannulated; however. the inferior mesenteric vein can be cannulated 
alternatively. as shown in Figure 177-6. Portal v. = portal vein; R. gastric a. = right gastric artery; Gastroduodenal a. = gastroduodenal 
artery; L. gastric a. = left gastric artery; Splenic a. = splenic artery; S.M.A. = superior mesenteric artery; Splenic v. with cannula = splenic 
vein with cannula; Sup. mesenteric v. encircled = superior mesenteric vein encircled. (See Color Plate.) 
Figure 177-8. Occlusion of the superior vena cava inflow and 
simultaneous clamping of the aorta prox.imal to the innominate artery. 
The aorta is also simultaneously clamped just above or below the 
diaphragm. Cardioplegic solution infused through the ascending aorta 
is allowed to run only in the heart. Sup. v.c. stapled = superior vena 
cava stapled; Inf. V.c. incised = inferior vena cava incised. (See Color 
Plate.) 
Pr ••• n.tlon 
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been completed, the heart is carefully dissected by the two 
teams, ensuring that enough pulmonary artery and left atrial 
cuff remain on the heart and the lungs, making them both 
available for transplantation.' After the heart has been re-
moved, the lung team can then proceed with extraction of 
the lungs. 
During this phase. the abdominal organs are untouched 
while they are exsanguinated and the cold perfusion is contin-
ued. After removal of the thoracic organs, the abdominal team 
proceeds with the final dissection and removal of the liver, 
pancreas. intestine, and kidneys. The technical steps have 
been outlined elsewhere by usso. 111-114 and others. II '-117 After 
the organ recovery, long segments of the iliac arteries and 
veins, inferior vena cava, and aortallS (and carotid arteries in 
children) should always be removed and stored under hypo-
thermic conditions. This ensures the ability to deal with all 
possible vascular problems that might be encountered during 
the reCipient operations. IIS- 123 
With the development of the intestinal and multivisceral 
transplant program at the University of Pittsburgh (see Chap-
ter 184). a technique was developed for the removal of essen-
tially the entire abdominal visceral bloc (Fig. 177-9) (see Color 
Plate). '" 12. Anatomic considerations are fundamental during 
intestinal and multivisceral procurement because recipients 
require different types of intestinal transplantation (isolated 
small bowel, liver and small bowel, true multivisceral, and so 
on) based on different diseases and needsY' These procure-
ment techniques do not interfere with those of other organs. 
In our first 35 intestinal donor operations, there were 62 
Figure 1n-9. En bloc harvesting of liver and small bowel from a 
pediatric donor. (See Color Plate.) 
·.5; 7 
kidneys, 35 livers, 18 hearts. and 3 lungs procured simultane-
ously.'o 
At the end of the operation, the procurement coordinator 
completes the form shown in Figure 177-3. These data and 
the other basic donor information collected earlier in the 
donor procurement process (Fig. 177-2) are of critical impor-
tance in the selection of the recipient and the outcome of the 
transplantation. The risk factors associated with an unfavor-
able outcome, at least in some organs, may be identified by 
the information readily available at the time of the multiple 
organ procurement. This knowledge can help us stratify pro-
spective donor-recipient combinations according to their pre-
dicted risk of failure, providing insight as to the probable 
outcome of individual patients and the factors that determine 
it. It can also be used to describe study populations, stratified 
according to their risk, and allow uniform comparison of 
outcomes. 
In Pittsburgh, we have completed an analysis determining 
that the outcome of a liver transplantation can be predicted 
at the time of the surgery. This may be achieved by using 
information obtained as part of a routine pretransplant recipi-
ent and donor work-up, which is always available at the time 
of organ allocation. IlS Because of the interaction of two differ-
ent biologic systems-the donor and the recipient-the out-
come of an organ transplantation is a complex phenomenon. 
Therefore, the various aspects of multiple donor organ pro-
curement discussed in this chapter should be carefully consid-
ered in each potential procurement scenario as fundamental 
to the success of the transplantation procedure. 
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Principles of Immunosuppression 
Ajai Khanna, MD, FRCS • Alan J. Rosenbloom, MD 
Clark Andrew Bonham, MD • John J. Fung, MD, PhD 
Recent advances in molecular biology and immunology have 
unraveled mechanisms of antigen-presenting cell (APC) and 
T cell interactions. TIlis includes elucidation of molecular 
mechanisms involved in the activation and turning otI of T 
cells and interleukin-2 (lL-2) gene transcription and transla-
tion. Studies leading to novel ways of inhibiting T cell activa-
tion have focused on various subunits (u, 13, and -y) of the IL-
l receptor. TIlis has led to an explosion of trials of these 
agents in combinations with more conventional immunosup-
pressive drugs. 
BASIC PRINCIPLES 
Optimal immunosuppression consists of drug therapy that 
enables gr.ltt acceptance while suppressing systemic immunity 
as little as possihle and producin~ the least systemic toxicity. 
Immunosllppression predisposes to intection and mali~nancvK 
in addition to other side eHects that are inherent risks with 
all the currently avai/able immunosuppressants. Blood level 
monitorin),( and titration of immunosuppression arc limited to 
only a tCw immunosuppressive agents. and in pr.tctice too 
much or too little immunosuppression almost invariably be-
comes apparent only in retrospect. purro~ate biologic assays. 
slich as suppression of the mixed lvmphocvte reaction. are 
dther impr.tctical or do not have proven clinical correlates. 
The timing. dosing. and selection of immunosuppressive 
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agents differ much. Current protocols use multiple drugs, 
each directed at a discrete site in the T cell-activation cas-
cade.' Most immunosuppressive regimens are combinations of 
drugs, often with different modes of action and tOxicity. This 
approach allows giving smaller doses of each drug. Trans-
plantation immunosuppression can be (1) pharmacologic, 
consisting of drugs like corticosteroids. cytokine suppressive 
agents, antiproliferative agents. and cytotoxic agents or (2) 
biologic, consisting of monoclonal and polyclonal antilympho-
cyte antibodies and anti-cytokine receptor antibodies. 2 Newer 
agents are being introduced. 
Tacrolimus (Tac) or cydosporine (CyA) with steroids forms 
the backbone of most immunosuppressive regimens being 
used today. An anti proliferative agent or an antilymphocyte 
antibody, or both, may be added. When acute cellular rejec-
tion occurs, it is common to treat it with large doses of 
steroids or antilymphocyte antibodies, or both. 
In general. the early postoperative period calls for the great-
est degree of immunosuppression. As time goes on, many 
patients can maintain graft function with smaller quantities of 
immunosuppressive agents. Some patients can tolerate com-
plete withdrawal of therapy without exhibiting rejection~; 
however. this is best done as a protocol-based strategy with 
patients under strict supervision. 
OVERVIEW OF TRANSPLANT 
IMMUNOBIOLOGY 
Lymphocytes are preprogrammed as they develop in the thy-
mus to recognize foreign antigen. Antigen specificity is deter-
mined by an antigen-binding unit on the T cell surface, the T 
cell receptor (TCR). TIle specifiCity and diversity of the bind-
ing site of the TCR derive from its amino acid composition 
and the variations in this composition from T cell to T cell. 
The gene sequence that codes for the TCR rearranges during 
development. so each T cell ends up with a different TCR-
binding specificity. Because the gene rearrangements are com-
pletely r.tndom, a huge library of binding sites capable of 
recognizing both self and foreign molecules is generated. Thy-
mocytes with TCRs that bind to self molecules (and thus 
potentiate the development of autoimmunity) are subse-
quently destroyed. by mechanisms that are poorly understood. 
Lymphocytes recirculate at a r.tte of I % to 2% per hour, 
migratin~ through all tissues of the bodv. Recirculation routes 
are not random. Specialized cell-surtace "homing" molecules 
on T lymphocytes mediate attachment to specific endothelial 
molecules in targeted tissues. Once inside tissue. antigen· 
presenting cells (APCs). such as macropha~esI make intimate 
contact with the lymphocytes and present foreign antigen 
that has been processed in the cells by the APCs. The APCs 
phagocytose foreign proteins and cleave toreign protein enzy-
matically into small peptides of eight to 12 amino acids length. 
These peptides are loaded onto a class of specialized carrier 
molecules known as the major lJisto(.'ompattbility complex 
(MHC). MHC molecules carry the peptide fr.tgments to the 
cell surface. where thcy are displayed to T cells. 
TIle TCR is a cell-surtace moleculc. The TCR associates with 
"accessory" molecules. including CD:'\ and either CD4 or CDB. 
The TCR-CD3 complex interacts with the pcptide fragment in 
the bindin~ groove of the MHC molecule of the APe. and this 
complex is st:lhilized hy the CD-l or CD8 molecule of the T 
cell. TIl is inter.tction produces the si),(nal that initiates activa-
tion of the T cell. leading to prolifer.ttion of that T cell clone. 
which reco~nizes the particular anti~en fragments of foreign 
protein. The basis tilr ~teC-restricted antigen recognition is 
the requirement tilr antigen presentation by APCs bearing an 
:'.tHC molecule specific to the host. 
Antigen-liirected proliteration of T cell clones is absolutelv 
